AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Investing1d
Novo Nordisk’s SWOT analysis: GLP-1 giant faces fierce competition in booming obesity market
Looking ahead, Novo Nordisk’s pipeline includes several promising candidates that could further strengthen its position in the metabolic disease space. Amycretin, a once-daily oral GLP-1/Amylin ...
Novo Nordisk under pressure as obesity drug disappoints in diabetes trial
Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.
pharmaphorum3d
Novo Nordisk’s oral amycretin tops Wegovy in obesity trial
Data on the subcutaneous version of amycretin is due next year, and Novo Nordisk also presented early data on another oral therapy, CBR1 inverse agonist monlunabant (INV-202), which showed a 3% ...
Morgan Stanley says REDEFINE-2 misses opportunity to differentiate in diabetes
Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety profile similar to ...
NovoNordisk stock falls on Roche-Zealand pact; Jefferies cuts target
Novo Nordisk (CSE:NOVOb) (NYSE:NVO) shares slumped Wednesday after Roche (SIX:ROG) struck a $5.3 billion deal to acquire rights to an obesity treatment from Denmark’s Zealand Pharma A/S (CSE:ZELA).
health.economictimes.indiatimes1d
Roche secures Zealand obesity drug candidate for up to $5.3 billion
but Novo Nordisk is banking on a dual mode of action that includes amylin for its next generation of drugs, with experimental compounds called amycretin and CagriSema. Disappointing clinical trial ...
Novo Nordisk shares jump after Wegovy price cuts announced
Novo Nordisk announced launching a direct-to-patient online pharmacy NovoCare, offering a more than half-price cut for its ...